BioSpace News Archive

Hyku Biosciences, Inc. (Hyku) today announced its launch with $56 million in seed financing to develop precision covalent medicines in oncology.

AIRNA today emerged from stealth with a $30 million initial financing led by ARCH Venture Partners.

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City, from September 26-28, 2023.

Aspargo Laboratories, Inc. (“Aspargo” or the “Company”), a privately held specialty pharmaceutical company focused on commercializing innovative formulations of leading tablet medications, announced today that all 47 subjects have received their initial dose in the Company’s comparative bioavailability study comparing Sildenafil Oral Suspension (ASP-001) to Viagra®.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today highlighted the industry-leading scale and speed in whole-slide, spatial biology workflows enabled by the recently launched PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platform upgrades.

Biora Therapeutics, Inc. announced an agreement with certain funds managed by Athyrium Capital Management, to increase their equity exposure while improving the company’s balance sheet.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial.

Dyadic International, Inc today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.

Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, and Kytopen, a leader in the development and commercialization of non-viral transfection tools for genome engineering, today announced a partnership to bring the power of cloud native, structured data to Kytopen’s Flowfect® platforms.

AMO Pharma Limited (“AMO Pharma”) today announced initial preclinical data from a study of the use of the company’s investigational therapy AMO-02 in the treatment of Duchenne muscular dystrophy (DMD).